跳至主要内容
临床试验/JPRN-UMIN000001061
JPRN-UMIN000001061已完成2 期

Phase II clinical trial of personalized peptide vaccination in patients with advanced/metastatic urotherial cancer previously treated with M-VAC chemotherapy - Peptide vaccination for patients with advanced/metastatic urotherial cancer previously treated with M-VAC chemotherapy

Kurume University School of medicine, Department of Immunology0 个研究点目标入组 20 人开始时间: 2008年3月10日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with multiple cancers 3) Patients with the past history of severe allergic reactions. Patients who are judged inappropriate for the clinical trial by doctors.

研究者

发起方
Kurume University School of medicine, Department of Immunology

相似试验